Latham & Watkins LLP represents Vistagen in the offering. Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for...
Vistagen’s US$100 Million Underwritten Offering
Vivid Seats’ Class A Common Stock Secondary Offering
Latham & Watkins represents Vivid Seats and the selling stockholder in secondary offering of Class A common stock. Vivid Seats Inc. (NASDAQ: SEAT), a leading marketplace...
Worthington Industries’ Steel Processing Business Spin-off
Latham & Watkins represented Worthington Industries in the transaction. Worthington Industries, Inc. (NYSE: WOR), a leading industrial manufacturing company, has announced that its Board of Directors unanimously...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
Decarbonization Plus Acquisition Corporation II’s Business Combination with Tritium
Vinson & Elkins LLP and Clifford Chance advised Decarbonization Plus Acquisition Corporation II on the business combination with Tritium Holdings Pty Ltd, represented by Corrs Chambers...